Medicare's New GLP-1 Discount Has a Catch — and the Sickest Patients Are Paying for It
The federal government launched its Medicare GLP-1 Bridge program in July with a headline number: $50 a month for weight-loss drugs like Wegovy and Zepbound. For millions of Medicare enrollees priced out of a $750 monthly prescription, that sounded like relief.
For Jeff La Marca, a 68-year-old resident of Basking Ridge, New Jersey, it sounded like a lifeline — until he was rejected.
La Marca has a BMI of 42, has undergone quadruple heart bypass surgery, is prediabetic, and carries a risk of stroke. He also has severe obstructive sleep apnea — and that diagnosis is precisely what disqualifies him from the $50 price. 'I'm obese, morbidly obese,' he said. 'I had quadruple heart bypass surgery. I'm at risk for stroke. I'm prediabetic. And yet I can't get it. I'm livid.'
The fine print that matters
Buried in the Bridge program's eligibility rules is a distinction with serious financial consequences. The $50 monthly cap applies only to patients using a GLP-1 solely for weight loss. Anyone whose diagnosis falls under an FDA-approved GLP-1 indication — Type 2 diabetes, moderate to severe obstructive sleep apnea — is instead redirected to their Medicare Part D prescription drug plan. Those plans can require copays of $200 to $600 a month, or more.
The program is an 18-month pilot. Eligible patients must be enrolled in Medicare Part D, and prior authorization requests bypass the insurer, going instead to a contractor system run for the Centers for Medicare & Medicaid Services. The pilot covers Wegovy, the KwikPen formulation of Zepbound, and the oral medication Foundayo.
'The Bridge program was designed to target those people who can't get GLP-1 coverage through Part D but would benefit from taking one for weight loss,' said Juliette Cubanski, who directs the Program on Medicare Policy at KFF.
The cost math — and who is left out
CMS spokesperson Timothy Foster said most prior authorization requests have been completed in under 12 hours, and that 'thousands of eligible beneficiaries' have already accessed the drugs at pharmacies nationwide.
The fiscal exposure is not trivial. Cubanski estimates that 3.8 million people qualify for Bridge. If a quarter of them enroll and remain on treatment for the full 18 months, the cost to Medicare reaches approximately $3.3 billion. If three-quarters enroll, that figure climbs toward $10 billion. Expanding the program to cover an additional 5.9 million overweight patients already eligible for Part D GLP-1 coverage would add billions more. The federal government has not released its own cost estimate.
Primary care physician Taylor Lacy, who practices at Sunflower Medical Group in Roeland Park, Kansas, put it plainly: ''Coverage' doesn't always mean 'affordable.'' She argued that the Bridge program is leaving behind patients with the greatest medical need — those who have already run the gauntlet of prior authorization and step therapy, only to reach the pharmacy counter and face a bill they cannot pay.
The market has already voted on affordability
About 1 in 5 American adults have taken a GLP-1 medication, and most — including those with private insurance — report the drugs are difficult to afford. Federal law has long barred Medicare from covering drugs prescribed solely for weight loss, which is what made the Bridge pilot notable when it launched.
But a program that charges its sickest enrollees the most is not a coverage expansion — it is a coverage illusion. The administrative state built a headline and buried the asterisk. Taxpayers are on the hook for up to $10 billion, and the patients with the most complex, costly conditions are still standing at the pharmacy counter doing the math. Capital rewards clear rules; so do patients. What they got here is neither.
